Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

被引:211
作者
Launay-Vacher, Vincent [1 ]
Rey, Jean-Baptiste [2 ]
Isnard-Bagnis, Corinne [1 ]
Deray, Gilbert [1 ]
Daouphars, Mikael [3 ]
机构
[1] Hop La Pitie Salpetriere, Dept Nephrol, ICAR, F-75013 Paris, France
[2] Hop Robert Debre, Dept Pharm, Reims, France
[3] Henri Becquerel Canc Ctr, Dept Pharm, Rouen, France
关键词
platinum salts; cisplatin; renal toxicity;
D O I
10.1007/s00280-008-0711-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).
引用
收藏
页码:903 / 909
页数:7
相关论文
共 61 条
[41]  
MUNCHAUSEN LL, 1975, CANCER CHEMOTH REP 1, V59, P643
[42]  
PERA MF, 1979, CANCER RES, V39, P1269
[43]   CROSSLINKING OF COMPLEMENTARY STRANDS OF DNA IN MAMMALIAN-CELLS BY ANTITUMOR PLATINUM COMPOUNDS [J].
ROBERTS, JJ ;
PASCOE, JM .
NATURE, 1972, 235 (5336) :282-&
[44]   UPTAKE AND METABOLISM OF CISPLATIN BY RAT-KIDNEY [J].
SAFIRSTEIN, R ;
MILLER, P ;
GUTTENPLAN, JB .
KIDNEY INTERNATIONAL, 1984, 25 (05) :753-758
[45]   MUTAGENIC ACTIVITY AND IDENTIFICATION OF EXCRETED PLATINUM IN HUMAN AND RAT URINE AND RAT PLASMA AFTER ADMINISTRATION OF CISPLATIN [J].
SAFIRSTEIN, R ;
DAYE, M ;
GUTTENPLAN, JB .
CANCER LETTERS, 1983, 18 (03) :329-338
[46]   CISPLATIN NEPHROTOXICITY - INSIGHTS INTO MECHANISM [J].
SAFIRSTEIN, R ;
WINSTON, J ;
MOEL, D ;
DIKMAN, S ;
GUTTENPLAN, J .
INTERNATIONAL JOURNAL OF ANDROLOGY, 1987, 10 (01) :325-346
[47]  
SAFIRSTEIN R, 1988, ORGAN DIRECTED TOXIC, P172
[48]  
SAFIRSTEIN R, 1980, FED PROC, V40, pA651
[49]  
SALEM P, 1984, CANCER, V53, P837, DOI 10.1002/1097-0142(19840215)53:4<837::AID-CNCR2820530403>3.0.CO
[50]  
2-L